



(12) **United States Patent**
Sawhney et al.

(10) **Patent No.:** **US 9,370,485 B2**
(45) **Date of Patent:** ***Jun. 21, 2016**

(54) **HYDROGEL POLYMERIC COMPOSITIONS AND METHODS**

31/4422 (2013.01); *A61K 31/4458* (2013.01);
A61K 31/496 (2013.01); *A61K 31/573*
(2013.01); *A61K 31/58* (2013.01); *A61K 47/10*
(2013.01)

(71) Applicant: **Incept, LLC**, Lexington, MA (US)

(58) **Field of Classification Search**
None
See application file for complete search history.

(72) Inventors: **Amarpreet S. Sawhney**, Lexington, MA (US); **William H. Ransone, II**, Waltham, MA (US)

(56) **References Cited**

(73) Assignee: **Incept, LLC**, Lexington, MA (US)

U.S. PATENT DOCUMENTS

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

3,949,750 A 4/1976 Freeman
3,995,635 A 12/1976 Higuchi et al.
(Continued)

(21) Appl. No.: **14/470,081**

FOREIGN PATENT DOCUMENTS

(22) Filed: **Aug. 27, 2014**

EP 1704878 9/2006
EP 1967220 9/2008
(Continued)

(65) **Prior Publication Data**
US 2014/0363498 A1 Dec. 11, 2014

OTHER PUBLICATIONS

Related U.S. Application Data

(63) Continuation of application No. 12/485,192, filed on Jun. 16, 2009, which is a continuation of application No. 11/825,848, filed on Jul. 9, 2007, now Pat. No. 9,125,807.

S Cohen, E Lobel, A Trevogoda, Y Peled. "A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye." *Journal of Controlled Release*, vol. 44, 1997, pp. 201-208.*
Z Liu, J Li, S Nie, H Liu, P Ding, W Pan. "Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin." *International Journal of Pharmaceutics*, vol. 315, 2006, pp. 12-17.*
B Srividya, RM Cardoza, PD Amin. "Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system." *Journal of Controlled Release*, vol. 73, 2001, pp. 205-211.*
(Continued)

(51) **Int. Cl.**
A61K 47/10 (2006.01)
A61K 9/00 (2006.01)
A61K 31/196 (2006.01)
A61K 31/405 (2006.01)
A61K 31/4422 (2006.01)
A61K 31/4458 (2006.01)
A61K 31/496 (2006.01)
A61K 31/573 (2006.01)
A61K 31/58 (2006.01)

Primary Examiner — Isaac Shomer
(74) *Attorney, Agent, or Firm* — Dardi & Herbert, PLLC; Curtis B. Herbert

(52) **U.S. Cl.**
CPC *A61K 9/0051* (2013.01); *A61K 31/196* (2013.01); *A61K 31/405* (2013.01); *A61K*

(57) **ABSTRACT**
Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreous site for controlled release of a therapeutic agent.

21 Claims, 14 Drawing Sheets

